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Aggregation of α-Synuclein (αS) protein to amyloid fibrils is a neuropathological hallmark
of Parkinson’s disease (PD). Growing evidence suggests that extracellular αS aggregation
plays a pivotal role in neurodegeneration found in PD in addition to the intracellular αS
aggregates in Lewy bodies (LB). Here, we identified and compared a diverse set of
molecules capable of mitigating protein aggregation and exogenous toxicity of αSA53T, a
more aggregation-prone αSmutant found in familial PD. For the first time, we investigated
the αS anti-amyloid activity of semi-synthetic flavonoid 2′, 3′, 4′ trihydroxyflavone or
2-D08, which was compared with natural flavones myricetin and transilitin, as well as
such structurally diverse polyphenols as honokiol and punicalagin. Additionally, two
novel synthetic compounds with a dibenzyl imidazolidine scaffold, Compound 1 and
Compound 2, were also investigated as they exhibited favorable binding with αSA53T.
All seven compounds inhibited αSA53T aggregation as demonstrated by Thioflavin
T fluorescence assays, with modified fibril morphology observed by transmission
electron microscopy. Ion mobility-mass spectrometry (IM-MS) was used to monitor the
structural conversion of native αSA53T into amyloidogenic conformations and all seven
compounds preserved the native unfolded conformations of αSA53T following 48 h
incubation. The presence of each test compound in a 1:2 molar ratio was also shown
to inhibit the neurotoxicity of preincubated αSA53T using phaeochromocytoma (PC12)
cell viability assays. Among the seven tested compounds 2-D08, honokiol, and the
synthetic Compound 2 demonstrated the highest inhibition of aggregation, coupled with
neuroprotection from preincubated αSA53T in vitro. Molecular docking predicted that
all compounds bound near the lysine-rich region of the N-terminus of αSA53T, where
the flavonoids and honokiol predominantly interacted with Lys 23. Overall, these findings
highlight that (i) restricted vicinal trihydroxylation in the flavone B-ring is more effective in
stabilizing the native αS conformations, thus blocking amyloidogenic aggregation, than
dihydroxylation aggregation in both A and B-ring, and (ii) honokiol, punicalagin, and
the synthetic imidazolidine Compound 2 also inhibit αS amyloidogenic aggregation by
stabilizing its native conformations. This diverse set of molecules acting on a singular
pathological target with predicted binding to αSA53T in the folding-prone N-terminal
region may contribute toward novel drug-design for PD.
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INTRODUCTION
Parkinson’s disease (PD) neuropathology is characterized by
loss of dopaminergic neurons, and in most cases, deposition of
Lewy bodies in the brain (Hughes et al., 1992). Aggregation and
amyloid formation of the cytosolic protein α-Synuclein (αS), in
both intracellular and extracellular areas, have been implicated
in the formation of Lewy pathology (LP) and degeneration of
dopaminergic neurons in the substantia nigra pars compacta
region of the brain (Baba et al., 1998; Volpicelli-Daley et al., 2011;
Luk et al., 2012; Iyer et al., 2014). Human αS is a 140-amino acid
residue polymorphic protein consisting of a membrane binding
N-terminal region, a non-amyloid β component (NAC) region
and an acidic C-terminal tail. This protein is associated with key
biological activities such as vesicle trafficking, maintenance of
the synaptic SNARE complex and vesicle pools, and regulation
of dopamine (DA) metabolism (Cabin et al., 2002; Sidhu et al.,
2004; Chandra et al., 2005; Cooper et al., 2006). Along with
the sporadic form of PD caused by wild type αS, a missense
point mutation in the snca gene results in the more aggregation
prone mutant αSAla53Thr (αSA53T), which has been found
to be associated with a familial form of PD (Polymeropoulos
et al., 1997; Narhi et al., 1999; Li et al., 2001; Papadimitriou
et al., 2016). Since current treatments for PD aim only at
replacing DA loss, and provide only transient symptomatic relief,
there is an urgent need for treatments that can directly modify
disease progression. Therefore, inhibition of αS aggregation, or
its pathological mutant αSA53T, provides a disease-modifying
therapeutic approach for PD, inclusive of its familial form.
The amyloidogenic aggregation of an intrinsically disordered
protein (IDP) such as αS involves formation of heterogeneous
and transient assemblies early in its aggregation pathway, that act
as a precursor for fibrillization (Bousset et al., 2013). Considering
the difficulty in gaining structural information on these
conformational assemblies, ionmobility-mass spectrometry (IM-
MS) is employed to monitor soluble αS conformations during the
early aggregation process. IM-MS is a sensitive tool for structural
study of conformational folding and other characterization
(Lanucara et al., 2014), and has been used for high-throughput
screening of amyloid inhibitors (Young et al., 2014). It allows
measurement of both the mass and collision cross section
(CCS) of an ion, and thereby can provide information on the
structural changes of amyloidogenic proteins such as αS during
aggregation and binding of small molecules (Bernstein et al.,
2004; Vlad et al., 2011; Liu et al., 2015). Combined with kinetic
analysis of fibrillization (such as from thioflavin T fluorescence
assays) and visualization of the fibrils using transmission electron
microscopy (TEM), IM-MS provides insights on the effect of
exogenous compounds on native αSA53T conformations in vitro.
This can inform on how such compounds interact during the
early stage of toxic amyloidogenic aggregation. Evaluation of
αSA53T neurotoxicity also provides valuable information on
the toxic nature of the observed aggregation products, and
possible neuroprotective effects of small molecule aggregation
inhibitors.
Various natural compounds have been shown to inhibit αS
aggregation or participate in remodeling of its fibrillization
pathway (Zhu et al., 2004; Masuda et al., 2006; Bieschke
et al., 2010; Morshedi et al., 2015). The polyphenolic flavonoids
baicalein and epigallo-catechin-3-gallate (EGCG) are amongst
these (Hong et al., 2008; Bieschke et al., 2010). Structurally,
baicalein possesses vicinal trihydroxyl groups only in the flavone
A-ring, whereas EGCG possesses vicinal trihydroxylation in
the B-ring and in the gallic acid moiety. Gallic acid, by itself,
also demonstrated inhibition of αSA53T aggregation (Liu et al.,
2014). A comprehensive study on flavonoid-induced inhibition
of αS aggregation has shown that vicinal dihydroxylation or
trihydroxylation improves inhibition irrespective of ring position
(Meng et al., 2009). However, except for baicalin, other reported
flavonoid inhibitors lack the localized single ring vicinal di
or tri hydroxyl groups. Thus, the importance of position and
extent of hydroxylation of flavonoids involved in inhibiting
αS aggregation and neurotoxicity is unclear. In this study,
we have investigated the anti-amyloid effect of semi-synthetic,
2′, 3′, 4′ trihydroxy flavone (2-D08) that has only vicinal
trihydroxylation in the B-ring. This flavone has shown improved
inhibition of amyloid β (Aβ) aggregation and toxicity through
its localized B-ring trihydroxylation (Marsh et al., 2017). We
compared it with myricetin, a known inhibitor of αS aggregation
(Meng et al., 2010; Liu et al., 2015) which also has vicinal
trihydroxylation in the B-ring along with -OH groups at flavone
3, 5, and 7 positions. Transilitin was also investigated here
to compare the effect of dihydroxylation in both A and B
rings. Our study provides information on the role of select
B-ring trihydroxylation for modulation of αS aggregation and
toxicity.
Other bioactive polyphenols investigated here for the
first time are the natural lignan compound honokiol and
ellagitannin punicalagin. Honokiol has demonstrated anti-
amyloid effects against amyloid beta (Aβ) (Hoi et al., 2010;
Das et al., 2016). Punicalagin, found in pomegranate, is
also a known inhibitor of Aβ protein aggregation and has
antioxidant and anti-inflammatory properties (Yaidikar et al.,
2014; Yaidikar and Thakur, 2015; Das et al., 2016). Extending
the structural diversity of molecules that can act on a
common target of pathological αS aggregation, we also included
two synthetic imidazolidine compounds, termed Compound
1 (1,3-dibenzyl-2-[3-(benzyloxy) phenyl] imidazolidine) and
Compound 2 (1,3-dibenzyl-2-[4-(benzyloxy)-3-methoxyphenyl]
imidazolidine), both bearing a five-membered heterocyclic
(FMH) imidazolidine ring scaffold. We previously identified
these compounds through virtual screening of the ZINC
chemical database and highlighted the importance of this
molecular scaffold with regards to preventing amyloid β
aggregation (Das and Smid, 2017). A summary of the compounds
investigated here is provided in Figure 1.
MATERIALS AND METHODS
Reagents and Chemicals
Myricetin, 2-D08, honokiol, and punicalagin were obtained
from Sigma-Aldrich (Castle Hill, VIC, Australia). Transilitin
was kindly provided by Dr. Peter Duggan at CSIRO
Materials Division (Clayton South, VIC, Australia). Synthetic
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FIGURE 1 | Chemical structures of (1) myricetin, (2) 2′, 3′, 4′ trihydroxy flavone or 2-D08, (3) transilitin, (4) honokiol, (5) punicalagin, (6) 1,3-dibenzyl-2-[3-(benzyloxy)
phenyl] imidazolidine or Compound 1, and (7) 1,3-dibenzyl-2-[4-(benzyloxy)-3-methoxyphenyl] imidazolidine or Compound 2.
imidazolidine Compound 1 and Compound 2 were sourced from
Specs (The Netherlands) and ChemDiv (U.S.A.) respectively,
both screening compound manufacturers. Purity of Compound
1 was assessed to be >97% through 1H NMR analysis
(Supplementary Figure 1), Compound 2 was certified with
a purity of>97%.
Thioflavin T, thiazolyl blue tetrazolium bromide (MTT),
trypan blue, DMSO, Roswell Park Memorial Institute 1640
(RPMI) medium and fetal calf serum (FCS) were obtained
from Sigma-Aldrich (St Louis, MO, USA). Non-essential amino
acids (NEAA), penicillin/streptomycin, 1× trypsin EDTA, and
phosphate buffered saline (PBS) at pH 7.4 were obtained from
Thermo Fisher Scientific, (Scoresby, VIC, Australia). Bovine
serum albumin (BSA) was obtained from Bovogen Biologicals
(East Keilor, VIC, Australia). Ammonium acetate was obtained
from Sigma-Aldrich (Castle Hill, VIC Australia).
Protein Expression and Purification
αSA53T was expressed and purified as previously described
(Volles and Lansbury, 2007). Cells were grown in normal
lennox broth (LB) medium. Protein was purified by size
exclusion chromatography using a Superdex 200 SEC column
(Bio Rad), with a flow rate of 0.5 ml/min, in 20mM ammonium
acetate buffer. The purity of αSA53T was confirmed by mass
spectrometry and samples were lyophilized and stored at −80◦C
until required.
Preincubation of αSA53T and Compound
Preparation
αSA53T was dissolved in 50mM ammonium acetate buffer (pH
not adjusted) to make 1mM stock solution, dispensed into
aliquots and immediately frozen at−80◦C until required. All test
compounds were initially diluted in DMSO and then in 50mM
ammonium acetate to their final stock concentrations prior to
incubation with αSA53T. The final concentration of DMSO in
each experiment was <1%. For the cell viability assay, 50µM
αSA53T alone or in the presence of each compound (100µM)
in 50mM ammonium acetate buffer was shaken at 300 rpm for
72 h at 37◦C.
Thioflavin T Fluorescence Assay
Thioflavin T (ThT) binds to β sheet rich structures present in
amyloid fibrils, with fluorescence increasing proportionally to the
quantity of fibrils present in solution. ThT (final concentration
100µM) was added to wells in a Greiner 96-well plate together
with αSA53T (100µM), in the absence or presence of each test
compound (either at 200 or 100µM) in 50mM ammonium
acetate buffer to a total volume of 100 µl in each well.
Fluorescence was measured at 37◦C every 30min for 100 h
using a Fluostar Optima plate reader (BMG Lab technologies,
Australia) with a 440/490 nm excitation/emission filter. The ThT
assay was performed in duplicate and repeated three times.
Results were normalized to blank values (ThT alone in 50mM
ammonium acetate buffer).
Transmission Electron Microscopy (TEM)
Imaging
TEM was used to visualize αSA53T aggregates and fibrils
and investigate the effects of selected compounds on fibril
morphology. Samples were prepared by adding 5–10 µl of
protein solution taken directly from the ThT assay after 100 h to a
400mesh formvar carbon-coated nickel electronmicroscopy grid
(Proscitech, Kirwan, QLD, Australia). After 1min, this sample
was blotted using filter paper. Ten microliters of contrast dye
containing 2% uranyl acetate was then placed on the grid, left
for 1min and blotted with filter paper. Grids were then loaded
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onto a specimen holder for analysis using a FEI Tecnai G2
Spirit Transmission Electron Microscope (FEI, Milton, QLD,
Australia). Sample grids were viewed using a magnification of
34,000–92,000X. Grids were extensively scanned manually in
search of fibrils and representative images were taken.
Ion Mobility-Mass Spectrometry (IM-MS)
Fifty micromolar αSA53T was prepared for IM-MS experiments
in 50mM ammonium acetate buffer in the absence and presence
of each compound at a molar ratio of 1:2 (protein: compound).
Samples were allowed to fibrillize by incubation at 37◦C with
constant shaking at 300 rpm. IM-MS analysis was performed
on an Agilent 6560 Ion Mobility Q-ToF spectrometer with
samples introduced by nanoelectrospray ionization through
platinum-coated capillaries (made in-house). Ions were analyzed
in the positive mode, with parameters systematically selected
to achieve optimal signal while avoiding any analysis induced
structural transitions (full details of optimization will be reported
in a manuscript currently in preparation). Typical instrument
parameters included; capillary voltage 1,700V, fragmentor
voltage 400V, gas temperature 0◦C, gas flow 2 l/min, trap fill time
20000.0 µs, trap release time 4000.0 µs and CCS measurement
was made using a multifield approach varying the IM drift tube
voltage between 1,200 and 1,700V. The acquired spectra were
processed using Qualitative Analysis B.07.00 and IM-MS browser
B.07.01 (both Agilent, Santa Clara, USA).
Neuronal Cell Culture, Treatment, and
Viability Measurements
Rat phaeochromocytoma cells (Ordway PC12) displaying a semi
differentiated phenotype with neuronal projections were kindly
donated by Professor Jacqueline Phillips (Macquarie University,
NSW, Australia) [21]. Cells were maintained in Roswell Park
Memorial Institute 1640 (RPMI) media with 10% fetal calf serum
(FCS), 1% L-glutamine, 1% non-essential amino acids, and 1%
penicillin/streptomycin. Cells were seeded at 2 × 104 cells per
well in RPMI with 10% FCS. PC12 cells were equilibrated for
24 h before treatment with preincubated αSA53T or preincubated
αSA53T in presence of each test compound. Cells were then
incubated for 48 h at 37◦C, 5% CO2 prior to measurement
of cell viability. After 48 h, PC12 cell viability was determined
using the thiazolyl blue tetrazolium bromide (MTT) assay. After
incubation, 96-well plates had all media removed and replaced
with serum-free media containing 0.25 mg/ml of MTT. The
plate was further incubated for 2 h at 37◦C with 5% CO2,
then the MTT solution was removed and cells were lysed with
DMSO. Absorbance wasmeasured at 570 nm using a SynergyMX
microplate reader (Bio-Tek, Bedfordshire, UK).
Statistical Analysis
Area under the curve analysis for Thioflavin T (ThT) fluorescence
data was interrogated using a one-way analysis of variance
(ANOVA) with a Dunnett’s multiple comparisons test to
determine the significance of each tested compound’s effect vs.
αSA53T alone. Data obtained from the MTT assay was analyzed
via a one-way ANOVA to assess neuronal cell viability with
a Holm–Sidak’s multiple comparison test used to determine
the significance level for each test compound interacting with
αSA53T. A significance value of p < 0.05 was used for
all experiments. Data analysis and production of graphs was
performed in GraphPad Prism 6 for Windows (GraphPad
Software, San Diego, USA).
Molecular Docking of Compound
Optimized Structure Binding to α Synuclein
To gain insight into the binding interactions of each selected
compound (ligand) with αSA53T, all ligand structures were first
optimized and then individually docked to αSA53T with 300
iterations per docking. Previous experimental evidence suggested
that the flavonoid binding site in α synuclein is near the lysine-
rich region of the N-terminus, with Lys21 or Tyr39 playing a
pivotal role (Meng et al., 2009). Therefore, the docking search
space was created centering this binding site with a radius of
25 Å covering these N-terminus residues. Ligand equilibrium
molecular geometries were optimized using a density functional
theory (DFT) method that utilizes the Becke-Lee-Yang-Parr
three-parameter hybrid functional (B3LYP) to ascertain accurate
bond distances, angles, dihedrals and optimized conformations
in the lowest energy state, using the Gaussian09 package of
codes (Frisch et al., 2016). A large basis set, aug-cc-pVDZ,
was used in approximation of optimized geometry for each
ligand. DFT-B3LYP level of calculations combined with a larger
basis set is considered as a standard and reliable method for
estimating optimized molecular geometry (El-Azhary and Suter,
1996). Fully optimized ligand structures were then allowed
to dock with the model αSA53T. Since the full sequence
αSA53T structure was not available, the solid-state NMR of
pathogenic α synuclein fibril (PDB ID: 2N0A) was obtained
from protein data bank and residue 53 mutated from alanine
to threonine to generate the model protein monomer of
αSA53T (Tuttle et al., 2016). The resultant αSA53T protein
conformation, without any further adjustment, was used for
docking, which employed CLC drug discovery workbench,
version 2.4.1 using a PLANTSplp empirical scoring function
(Korb et al., 2009).
RESULTS
Significant Inhibition of αSA53T Amyloid
Fibril Formation by All Test Compounds
The amyloid fibrillization of αSA53T was measured by a ThT-
based kinetic assay, which demonstrated a gradual increase
in fluorescence (relative fluorescence unit or RFU) up to the
first 50 h and then stabilized over the remainder of the assay,
indicating αSA53T underwent a conformational transition to a
cross-β-sheet rich structure characteristic of amyloid fibrils and
aggregates (Figure 2A). All test compounds: 2-D08, myricetin,
transilitin, honokiol, punicalagin, Compound 1 and Compound
2 inhibited the ThT fluorescence over the entire 100 h time
course of the assay at a 1:2 (protein: compound) molar ratio.
Area under the curve analysis showed extensive and significant
overall inhibition of fibril formation in the presence of each of
the test compounds at a 1:2 (protein: compound) molar ratio
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FIGURE 2 | (A) ThT fluorescence assay representing kinetics of (100µM)
αSA53T fibrillisation over 100 h, alone and in the presence of each test
compound at a 1:2 (protein: compound) molar ratio. (B) Representative area
under the curve (AUC) measurements demonstrating significant reductions in
ThT fluorescence for each test compound at a 1:2 (protein: compound) molar
ratio. [****p < 0.0001, F (7, 17) = 15.96; mean ± SEM of n = 3 experiments].
(Figure 2B). Further ThT assays at a 1:1 (protein: compound)
molar ratio also exhibited significant fibril inhibition, though
Compound 1 was the least effective among all compounds
tested (Supplementary Figures 2a,b). The mean RFU along with
the respective standard error of mean (SEM) values for each
compound are provided as Supplementary Table 1.
Transmission Electron Microscopy of
αSA53T Fibrils and Aggregates
False positives for ThT inhibition can occur when some
polyphenols undergo spontaneous oxidation in aqueous solution
and strongly quench ThT fluorescence, and this also might have
resulted in negative RFU for myricetin and punicalagin (Coelho-
Cerqueira et al., 2014). Therefore, the inhibition of fibrillization
observed in ThT assays was further confirmed by TEM, an
essential qualitative technique to characterize the morphology
of amyloid fibril and aggregate formation. The morphology
of αSA53T fibrils and aggregates appeared to be affected by
incubation with each of the test compounds at a 1:2 (protein:
compound) molar ratio, after 100 h incubation (Figures 3a–h).
TEM evidence demonstrated that αSA53T alone formed dense
fibrillar aggregates where several fibrils were intertwined and
arranged as rope-like mature amyloid fibrils, similar to those
observed previously (Bharathi et al., 2007; Figure 3a). Incubation
with Compound 2, myricetin and transilitin resulted in shorter,
thinner, and loosely attached fibrils, but in low abundance
(Figures 3c,e,h). Incubation with honokiol produced loosely
attached, short and long fibrils while punicalagin incubation
produces loosely attached, thin fibrils that were comparatively
longer (Figures 3f,g). Incubation with 2-D08 resulted in
amorphous aggregates of very short fibrils (Figure 3d), while
incubation with Compound 1 produce short fibrils and small
dense aggregates (Figure 3b). In the presence of all test
compounds, no rope-like aggregates were observed compared to
αSA53T alone. Additional TEM images following 50 h incubation
highlighted the formation of pre-fibrillar structures by αSA53T
alone. In the presence of all compounds except punicalagin, small
aggregate-like structures were observed. Punicalagin incubation
resulted in a few protofibrillar αSA53T structures similar to those
that were observed following 100 h incubation (Supplementary
Figure 3).
Preservation of Early αSA53T
Conformations by Test Compounds
Monitored Using IM-MS
IM-MS was utilized to investigate the αSA53T conformational
changes occurring early during aggregation in the presence and
absence of each test compound. An effective amyloid inhibitor
compound would not only prevent fibril formation, but also
preserve the protein in its natively unfolded state. IM-MS has
important application for investigating the early aggregation
phenomena of amyloidogenic proteins, since the unfolded native
proteins convert into a compact folded conformation that
precedes fibrillization (Smith et al., 2010; Liu et al., 2014). The
mass spectrum of αSA53T prior to incubation displayed a broad
charge state distribution consistent with a natively unstructured
protein (Konermann and Douglas, 1998; Figure 4A). The
measured CCSs for monomeric αSA53T ions prior to incubation
were plotted in Figure 4B, and are in agreement with previously
reported IM-MS measurements of the αSA53T monomer (Liu
et al., 2011). Lower charge states having a lower CCS represent
the population of ions with more compact structure, while from
charge states+8 to+9 the CCS measured increases significantly,
indicative of a transition from compact to extended structures.
A similar observation was reported previously for wild type
α-synuclein (Bernstein et al., 2004).
Following 48 h incubation, IM-MS analysis showed that
αSA53T ions of both lower and higher charge states from
+7 to +12 underwent a structural collapse as indicated by a
notable decrease in measured CCSs. Notably, when αSA53T was
incubated in the presence of inhibitor compounds, the measured
CCS values of the monomers revealed that the protein mostly
remained in its native conformation after 48 h, with honokiol
or 2-D08 shown to be most effective (Figure 4B). Among the
flavones, CCSs of αSA53T in the presence of myricetin or 2-D08
or transilitin were comparable.
To simplify the analysis of αSA53T conformations in the
presence of each test compound, we selected a single charge
state, +11, for comparison of CCSs based on the data shown
in Figure 4B. This charge state was selected as ion populations
at higher charge states tend to display a single, narrow feature
in the arrival time distribution and it showed remarkable
collapse of unfolded conformations, from 2,937 to 2,520 Å2
following 48 h of incubation. Incubation of αSA53T in the
presence of punicalagin, myricetin, transilitin, Compound 2
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FIGURE 3 | Representative transmission electron micrographs of αSA53T fibril and aggregate formation, following 100 h incubation alone and with each test
compound at a 1:2 (protein: compound) molar ratio; (a) αSA53T alone and in presence of (b) Compound 1, (c) Compound 2, (d) 2-D08, (e) myricetin, (f) honokiol,
(g) punicalagin, and (h) transilitin. Scale bar: 200 nm.
FIGURE 4 | (A) IM-MS spectrum of αSA53T (50µM) in 50mM ammonium acetate. (B) Plot of CCS vs. charge state for the dominant peaks in the IM-MS spectrum
measured for αSA53T at 0 h (circles) and following incubation in the absence (squares) and presence of 1:2 (protein: compound) honokiol (triangles) or 2-D08
(diamonds). Where multiple features were observed in the ATD, CCS is plotted for each feature. (C) Experimentally derived CCSs for the +11-charge state (m/z 1,317)
of αSA53T following 48 h incubation at 37◦C with shaking at 300 rpm.
and Compound 1 preserved the CCS of the 11+ ions close to
the preincubation measurement after 48 h (Figure 4C). Detailed
CCSs measurements of all these compounds for each charge state
is provided in Supplementary Figures 4a–e. Overall, all seven
test compounds demonstrated inhibition of the early structural
collapse of αSA53T during aggregation, with honokiol and 2-D08
being the most effective as evidenced by preventing the decrease
in CCSs.
Frontiers in Chemistry | www.frontiersin.org 6 May 2018 | Volume 6 | Article 181
Das et al. Diverse Inhibitors of α-Synuclein Aggregation
FIGURE 5 | Cell viability of PC12 cells described by an MTT assay following
48 h incubation of preincubated (for 72 h) 50µM αSA53T alone or with each
test compounds at a 1:2 (protein: compound) molar ratio. [****p < 0.0001;
F (3, 11) = 21.61 for Compound 1, Compound 2, and punicalagin and ****p <
0.0001; F (4, 17) = 21.77 for 2-D08, myricetin, honokiol, and transilitin; mean ±
SEM of n = 4 experiments].
Effects of Compounds on Fibrilar αSA53T
Mediated Neuronal Toxicity
Analysis of cell viability as determined by the MTT assay
demonstrated that preincubated αSA53T (50µM) alone evoked
about 50% loss of cell viability over 48 h (Figure 5). In contrast,
preincubated αSA53T in the presence of each test compound
at a 1:2 (protein: compound) molar ratio prevented the loss
of cell viability significantly (Figure 5). PC12 cells exposed to
preincubated αSA53T in the presence of 2-D08, myricetin, or
honokiol (100µM each) did not show any loss of cell viability.
This finding implies that interaction of these compounds with
αSA53T inhibited the neurotoxicity of the resultant fibrils toward
PC12 cells in vitro. The two synthetic imidazolidines, Compound
1 and Compound 2 also significantly mitigated the loss of cell
viability compared to αSA53T alone, however, the degree of
neuroprotection was not as pronounced as the other natural test
compounds (Figure 5). In a 1:1 (protein: compound) molar ratio,
only Compound 2, 2-D08, myricetin, honokiol, and punicalagin-
treated significantly reversed the loss of cell viability from
αSA53T (Supplementary Figure 5). The mean percentage cell
viability along with respective SEM values for each compound
are provided as Supplementary Table 2.
Molecular Modeling of Optimized
Conformations of Test Compounds to αS
A53T
Results from docking studies indicated that all the test
compounds bound near the lysine-rich hinge area ranging from
residue Ala 17 to Gly 36 in the predefined docking search space
(Figures 6A–D and Supplementary Figures 6a–c). Both synthetic
imidazolidines Compound 1 and Compound 2 displayed higher
docking scores and steric interactions than the rest of the
ligands; however, neither formed any H-bonding interactions
(Table 1; Figures 6A,B). The two trihydroxy flavones, 2-D08 and
myricetin, yielded similar scores, with myricetin forming more
H-bonding interactions than 2-D08. Transilitin, a dihydroxy
flavone, had similar docking and H-bonding scores as myricetin.
The lignan honokiol had the highest score among the natural
compounds, indicating strong interaction and H-bonding to
Lys 23 and Thr 33 while the ellagitannin punicalagin had
the lowest score, implying punicalagin might be a poor
binder to αSA53T. H-bonding with key Lys residues, especially
Lys 23 and Lys 21 was found in the case of all tested
natural ligands.
DISCUSSION
A growing number of studies have emphasized that
accumulation or aggregation of α-synuclein plays a key
role in neurodegeneration via mitochondrial and lysosomal
dysfunction (Hashimoto et al., 2003; Mazzulli et al., 2016).
A search for αS aggregation inhibitors possessing different
molecular scaffolds, other than the commonly used dopamine
analogs would be insightful for rational drug design. This study
has identified and compared the neuroprotective properties
of common and novel flavones as well as other polyphenols,
along with two synthetic imidazolidine compounds, which
can attenuate the toxic aggregation of αSA53T in vitro. The
seven compounds studied here can be broadly divided into
four categories, based on their structures; (i) the flavones:
myricetin, 2-D08 and transilitin, (ii) neolignan: honokiol,
(iii) ellagitannin: punicalagin, and (iv) synthetic dibenzyl
phenyl imidazolidines: Compound 1 and Compound 2.
Molecular docking provided additional insight into their
probable binding sites and the nature of interactions that
might contribute to structural modification of αSA53T
during fibrillization, to result in the formation of non-toxic
aggregates.
Interaction of Flavones and Their Effect on
αSA53T Conformation, Fibrillization, and
Neurotoxicity
The three flavones studied here possessed a catechol-type vicinal
tri-hydroxylation in the B-ring (myricetin and 2-D08) and di-
hydroxylation in both A and B-rings (transilitin). A major aim
of this study was to investigate how restricted tri-hydroxylation
in the flavone B-ring (2-D08) impacts αS amyloid aggregation.
TEM imaging revealed that 2-D08 altered the fibril morphology
more significantly than myricetin or transilitin, despite similar
ThT fluorescence outputs, in particular, TEM images after 50 h
incubation revealed that 2-D08 modified the αSA53T active
fibrillisation phase differently than myricetin or transilitin. The
amorphous αSA53T aggregates arising from incubation with 2-
D08 are likely to possess a reduced hydrophobic surface that
is critical for ThT micellar binding, thus lowering fluorescence
(Khurana et al., 2005). These amorphous aggregates resemble α-
Synuclein treated with baicalein as observed in a previous study
(Hu et al., 2016). Notably, 2-D08 showed an exclusive interaction
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FIGURE 6 | Binding modes of the four strongest inhibitor optimized ligand structures to αSA53T monomer: (A) Compound 2, (B) 2-D08, (C) honokiol, and
(D) punicalagin.
with Lys 23, followed by Thr 33 and unlike transilitin and
myricetin. Therefore, restriction of the O-quinone forming three
-OH side groups in either the A or B-ring of the flavone might
be favorable for binding to inhibit αS fibrillization as previously
observed with baicalein (Hong et al., 2008). Nevertheless, the
primary interaction of 2-D08 with αSA53T could be a low
affinity, transient interaction between the protein and ligand
rather than covalent modification of the Lys and Thr residues
in the binding region, as we did not observe significant adduct
formation in our IMMS study. Gallic acid had been shown to
inhibit αSA53T structural collapse in a similar manner (Liu et al.,
2014).
We previously reported that 2-D08 exerted a novel anti-
aggregatory and neuroprotective effect against Aβ compared
to transilitin and quercetin, which have A and C-ring
hydroxylation (Marsh et al., 2017). In the present study, 2-
D08 induced inhibition of αS aggregation and neuroprotection
was as pronounced as myricetin, a generic amyloid aggregation
inhibitor, and supports the idea that restricted B-ring tri-
hydroxylation is adequate for targeting both αS and Aβ (Ono
and Yamada, 2006; Hirohata et al., 2007; Zelus et al., 2012;
Liu et al., 2015). From the TEM imaging, it appeared that
transilitin modified the αSA53T fibrils in a similar way to
myricetin, where only loose fibrils but no amorphous aggregates
were seen. It is likely that these two flavones with A-ring
hydroxylation share a common mechanism for inhibiting
aggregation by reducing toxic amyloidogenic fibrils, whereas
2-D08 may inhibit amyloid fibrillization through formation
of non-toxic amorphous aggregates. Consequently, within the
flavone molecular scaffold, both 2-D08 and transilitin appear
to be generic inhibitors of αSA53T and Aβ aggregation,
similar to myricetin. Comparing the strong inhibitory effect
of transilitin with the flavonoid G-500 suggests that additional
hydroxyl groups other than the two pairs in the A and C-
rings might be redundant (Meng et al., 2010). Together, our
findings emphasize the previously reported idea that vicinal
trihydroxylation in the flavone is favorable for strong inhibition
of αS aggregation, coupled with its precise position in the B-ring
(Meng et al., 2010).
IM-MS is an emerging analytical method that retains weak
non-covalent interactions in the gas-phase andmaintains protein
conformations from solution phase (Konermann and Douglas,
1998; Sarni-Manchado and Cheynier, 2002; Wyttenbach and
Bowers, 2011; Abzalimov et al., 2012). The IM-MS study
presented here reinforces that soluble αSA53T undergoes a
structural transition from natively unfolded to more compact
amyloidogenic conformations at an early stage of aggregation, as
measured by changes in CCSs. This is consistent with our ThT
results, where the increasing fluorescence reaches its maximum
by ∼50 h, indicating the fibril plateau phase is reached in this
time frame. Stabilization of unfolded αSA53T conformations
to prevent amyloid formation was observed by IM-MS in the
presence of all three flavones tested and was further supported
by inhibition of ThT fluorescence during this early aggregation
period.
No loss in PC12 cell viability was observed in vitro by
preincubated αSA53T in the presence of 2-D08, even at
an equimolar concentration, corroborating that the loose
Frontiers in Chemistry | www.frontiersin.org 8 May 2018 | Volume 6 | Article 181
Das et al. Diverse Inhibitors of α-Synuclein Aggregation
TABLE 1 | Docking profiles of seven test compounds to αSA53T monomer.
Ligand Docking score H-bond forming residues H-bond score Steric interaction score RMSD (Å)
Compound 1 −69.23 − 0.00 −73.48 133.13
Compound 2 −65.53 − 0.00 −68.25 136.99
2-D08 −44.89 Lys 23, Thr 33 −6.00 −40.88 137.15
Myricetin −41.82 Ala 19, Lys 21, 23, Thr 22, Gln 24, Gly 25 −10.45 −32.68 129.40
Honokiol −58.36 Lys 23, Thr 33 −6.00 −55.55 137.42
Punicalagin −38.00 Lys 21, Lys 23 −5.83 −38.28 131.27
Transilitin −50.09 Lys 23, Lys 32, Thr 33, Lys 34 −10.00 −44.82 136.70
amorphous aggregates formed under these conditions are
not amyloidogenic or toxic. The prevention of structural
collapse by 2-D08 effectively inhibited the toxic amyloid
formation of αSA53T, providing a degree of neuroprotection
as pronounced as myricetin. Transilitin, on the other hand,
was less effective in halting αSA53T amyloidogenic aggregation
and neurotoxicity at an equimolar concentration. Since there
is some degree of αSA53T folding as measured by CCSs in
the presence of transilitin, this might account for the reduced
neuroprotection at a lower concentration. Combining the
anti-aggregation and neuroprotection results, we can infer
that flavone tri-hydroxylation is more effective against toxic
αSA53T amyloidogenic aggregation than di-hydroxylation. An
understanding of the precise flavone structural requirements for
strong inhibition of αS toxic aggregation would facilitate
improved drug design. As exemplified with quercetin,
hydroxylation in the flavone 3 and 7 positions are susceptible
to thiol formation with cellular proteins rather than being
neutralized in the cellular antioxidant network (Jacobs et al.,
2011). Therefore, not having any hydroxylation in these positions
while retaining a strong inhibitory effect seems a valuable strategy
for improved drug design. Consequently, 2-D08 would be more
favorable than myricetin to serve as a template for flavone-based
inhibitors of αS toxic aggregation.
Lignan Interaction With αSA53T During
Fibrillization and Neurotoxicity
Outside the flavonoid class of compounds, other small molecule
polyphenolics such as lignans have recently gained attention
for amyloid inhibition. In the present study, honokiol showed
a profound effect on αSA53T aggregation, as indicated by
the TEM imaging and ThT assay. TEM images of honokiol-
treated αSA53T fibrils to some extent resembled analogous
samples with punicalagin when comparing the long fibrils, and
transilitin when comparing the short fibrils. These modified
fibrils might account for the residual ThT fluorescence. As a
strong inhibitor, honokiol prevented the structural collapse of
native monomeric αSA53T at a very early stage of aggregation,
as observed for 2-D08, although treatment with honokiol did
not produce any amorphous aggregates. TEM images following
50 h incubation suggested that honokiol effectively inhibited
αSA53T fibrillization at an early stage, in agreement with the
ThT and IM-MS results. The demonstrated neuroprotection
by preincubated αSA53T fibrils in the presence of honokiol
highlights the non-toxic and non-amyloidogenic nature of the
detached fibrils observed. Molecular docking results indicated
that honokiol has the highest overall and steric binding scores
among the natural compounds, while interacting strongly with
key residues Lys 23 and Thr 33 through hydrogen-bonding,
a similar interaction observed in the docking profile of 2-
D08. This indicated a more sterically favorable interaction
with this binding region to stabilize the unfolded αSA53T
monomer. Nonetheless, honokiol lacks any O-quinone forming
vicinal dihydroxyl structure like 2-D08 or other catechol-type
flavones. Therefore, it might not covalently modify the target
but interact throughpi-pi stacking. Presumably, honokiol and tri-
hydroxyflavones such as 2-D08 or myricetin might have different
modes of interacting with αSA53T, nevertheless, they all result
in similar degree of inhibition of amyloidogenic aggregation.
Previously, honokiol was reported to be effective against toxicity
related to Aβ and calcitonin aggregation (Guo et al., 2015; Das
et al., 2016), and shown to be as effective as resveratrol and EGCG
in an in vivo model of Aβ toxicity, inhibition of cholinesterase
and metal chelation (Kantham et al., 2017). Together, honokiol
has as pronounced an effect as the two tri-hydroxyflavones
on inhibiting αSA53T aggregation and toxic amyloidogenic
formation. Nonetheless, the molecular mechanism underlying
this lignan based inhibition of αS aggregation is yet to be fully
understood.
Effect of Ellagitannin on αSA53T
Fibrillization and Neurotoxicity
Punicalagin, being the largest molecule tested, presents
interesting information on the role of steric bulk. Like the
flavones and honokiol, punicalagin also maintained the natively
unfolded structure of αSA53T in its early stage of aggregation.
Seemingly, the thin, long fibrils arising from punicalagin-
treated αSA53T might not be toxic amyloid fibrils, as it exerted
significant neuroprotection to αSA53T-exposed PC12 cells.
These fibrils might have undergone a loss of hydrophobic
surface area where ThT micelles could bind, thus diminishing
fluorescence output (Khurana et al., 2005). Not surprisingly,
molecular docking predicted that punicalagin was a poor binder
to αSA53T, possibly due to steric hindrance as a result of its bulky
size, however, it was predicted to form H-bonding interactions
with key Lys 21 and 23 like other natural polyphenols tested here.
Having multiple vicinal hydroxylation sites across the molecule,
it is highly probable that punicalagin has several interaction
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modes with polar residues in an unfolded protein. Therefore,
it is possible that punicalagin interacted with these predicted
residues to preserve an unfolded conformation that resulted in
non-amyloidogenic fibril formation. This was further supported
by the TEM study following 50 h incubation. Due to the bulky
size, punicalagin might have weak, non-specific interactions,
not binding to a particular pocket unlike other small molecule
polyphenolics. There is a correlation between the antioxidant
activity of flavonoids and their in vitro inhibitory effect on αS
fibrillization (Meng et al., 2009). We previously showed that
punicalagin was capable of inhibiting amyloid β aggregation
and neurotoxicity (Das et al., 2016). Given punicalagin has
some similarities in terms of being an extensively hydroxylated
polyphenol, its high antioxidant activity might also contribute
toward its inhibitory effect.
Novel Dibenzyl Imidazolidine Scaffold
Effect on αSA53T Fibrillization and
Neurotoxicity
Our previous study employing structure-based virtual screening
for Aβ1−42 inhibitors identified two compounds with anti-
aggregatory and neuroprotective roles in vitro (Das and Smid,
2017). These two synthetic compounds bearing a novel dibenzyl
imidazolidine scaffold could provide insight on the effect of
this scaffold on αSA53T aggregation in comparison with natural
polyphenolics. TEM imaging suggests that the αSA53T fibril
morphology, modified by both compounds, is different than that
induced by the polyphenolics. Nonetheless, the TEM study after
50 h incubation showed that αSA53T modified by Compound
2 resembled the morphology of myricetin-incubated samples.
Furthermore, there is variable effect on fibril morphology
between these two compounds. In the presence of Compound
1, the small dense aggregates look different than the amorphous
aggregates produced by 2-D08. The presence of both aggregates
and short fibrils indicate that Compound 1might have more than
one mechanism of interaction with αSA53T during aggregation.
The docking study predicted no polar interactions between
Compound 1 and αSA53T and showed higher docking scores,
suggesting a non-stable protein-ligand interaction. The reduction
of CCSs for some αSA53T charge states in the presence of
Compound 1 indicates it is less effective in stabilizing the native
αSA53T unfolded state. Therefore, interaction of Compound 1
with αSA53T might not completely prevent its amyloidogenic
aggregation, especially at lower concentration, unlike the natural
polyphenolics and Compound 2. This was further supported
by the comparative neurotoxicity observed in PC12 cells, and a
higher ThT fluorescence at equimolar concentrations of protein:
compound.
In the case of Compound 2, the appearance of thin, long fibrils
but no dense aggregates points toward a different mechanism
of interaction with αSA53T than Compound 1. There is
some degree of similarity between αSA53T fibrils formed by
Compound 2 andmyricetin. However, Compound 2 had amostly
sterically favorable binding to αSA53T, while myricetin has both
steric and polar interactions observable from the docking study.
Compound 2 demonstrated significant neuroprotection and low
ThT fluorescence at an equimolar concentration of protein:
compound. Improved inhibition of αSA53T toxic amyloid
aggregation by Compound 2 over Compound 1 is feasibly
attributable to the additional -OCH3 functional group adjacent
to the phenyl group in the dibenzyl imidazolidine scaffold in
Compound 2. This finding is consistent with our previous study
on these compounds against Aβ1−42, where we found that
Compound 2 significantly inhibited Aβ1−42 aggregation in both
ThT and TEM analysis, whereas Compound 1 was not able to
inhibit ThT fluorescence (Das and Smid, 2017). Considering
the novel aspect and effectiveness of both compounds bearing
this dibenzyl imidazolidine scaffold, our findings highlight
the potential of this molecular scaffold when targeted against
pathological amyloidogenic proteins.
CONCLUSION
Among the seven compounds tested and compared here,
polyphenols such as 2-D08, honokiol, myricetin, punicalagin,
and the synthetic imidazolidine, Compound 2 are the most
effective inhibitors of αSA53T toxic amyloidogenic aggregation,
while transilitin and other synthetic imidazolidines, such as
Compound 1, were less effective. All of these compounds
inhibited toxic amyloidogenic aggregation by stabilizing the
native unfolded αSA53T conformations, which in turn altered
αSA53T fibril morphology. This structurally diverse group of
molecules could potentially facilitate improved drug design
targeting the complexity of progressive neurodegenerative
diseases associated with amyloidogenic protein aggregation.
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